FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2140998439> ?p ?o ?g. }

• W2140998439 endingPage "456" @default.
• W2140998439 startingPage "449" @default.
• W2140998439 abstract "BACKGROUND This study was conducted to determine whether the paranasal extension of a primary non-Hodgkin's lymphoma (NHL) of the nasal cavity has any deleterious effect on patient outcome. METHODS One hundred and seventy-five patients with previously untreated nasal NHL were reviewed. There were 2 with low grade, 107 with intermediate grade, 17 with high grade, and 49 with unclassifiable lymphomas. In 48 cases the immunophenotype was available and 46 were T-cell lymphoma. According to the Ann Arbor system, there were 133 patients with Stage IE, 28 with Stage IIE, 4 with Stage IIIE, and 10 with Stage IVE lymphomas. Stage IE was subdivided into limited Stage IE (i.e., confined to the nasal cavity [67 patients]) or extensive Stage IE (i.e., presenting with extension beyond the nasal cavity [66 patients]). For patients with limited Stage IE disease the treatment of choice was radiotherapy with or without chemotherapy. In patients with extensive Stage IE disease, treatment was comprised of a combination of chemotherapy and radiotherapy or radiotherapy alone. For patients with a more advanced stage of disease (IIE-IVE), chemotherapy was an integral part of the treatment and was completed by irradiation, especially for patients with Stage IIE disease. RESULTS The actuarial overall survival (OS) and disease free survival (DFS) rates at 5 years for the whole group were 65% and 57%, respectively. The 5-year OS and DFS rates were influenced by stage, with a gradual decrease from 75% and 68% for Stage IE disease to 35% and 28% for Stage IIE disease, and 31% and 19% for Stage IIIE/IVE disease. Patients with limited Stage IE disease survived significantly longer (90% 5-year OS) compared with those with extensive Stage IE disease (57% 5-year OS; P < 0.001). For 67 patients with limited Stage IE disease, the 5-year OS was 89% with radiotherapy alone and 92% with radiotherapy and chemotherapy, whereas for 66 patients with extensive Stage IE disease, the 5-year OS was 54% with radiotherapy and 58% with combined modality therapy or chemotherapy (P > 0.05). CONCLUSIONS The prognosis of patients with primary NHL of the nasal cavity is stage dependent. In this large cohort of Stage IE patients, it was demonstrated that the paranasal local extension was a significant prognostic factor associated with poorer treatment outcome. The authors believe that Ann Arbor Stage IE should be subclassified further into limited and extensive Stage IE. The addition of chemotherapy did not appear to modify significantly the survival of patients with either limited or extensive Stage IE disease. The extranodal progression observed in patients with extensive Stage IE and Stage IIE-IVE disease clearly illustrates the need for improvement of systemic treatment. Cancer 1998;83:449-456. © 1998 American Cancer Society." @default.
• W2140998439 created "2016-06-24" @default.
• W2140998439 creator A5014686229 @default.
• W2140998439 creator A5016989239 @default.
• W2140998439 creator A5027776467 @default.
• W2140998439 creator A5039785424 @default.
• W2140998439 creator A5059710149 @default.
• W2140998439 creator A5063513320 @default.
• W2140998439 creator A5067714130 @default.
• W2140998439 creator A5075667735 @default.
• W2140998439 creator A5087921958 @default.
• W2140998439 date "1998-08-01" @default.
• W2140998439 modified "2023-09-27" @default.
• W2140998439 title "Primary non-hodgkin's lymphoma of the nasal cavity" @default.
• W2140998439 cites W15966455 @default.
• W2140998439 cites W1599858297 @default.
• W2140998439 cites W1793094955 @default.
• W2140998439 cites W1892168086 @default.
• W2140998439 cites W1965526826 @default.
• W2140998439 cites W1974720011 @default.
• W2140998439 cites W1982289372 @default.
• W2140998439 cites W1998232973 @default.
• W2140998439 cites W1999663037 @default.
• W2140998439 cites W2001779544 @default.
• W2140998439 cites W2003292270 @default.
• W2140998439 cites W2008140811 @default.
• W2140998439 cites W2010463145 @default.
• W2140998439 cites W2015177762 @default.
• W2140998439 cites W2034743452 @default.
• W2140998439 cites W2038252730 @default.
• W2140998439 cites W2041760744 @default.
• W2140998439 cites W2046168674 @default.
• W2140998439 cites W2054424391 @default.
• W2140998439 cites W2076163741 @default.
• W2140998439 cites W2077457701 @default.
• W2140998439 cites W2083689389 @default.
• W2140998439 cites W2084408104 @default.
• W2140998439 cites W2090821308 @default.
• W2140998439 cites W2091953646 @default.
• W2140998439 cites W2102826458 @default.
• W2140998439 cites W2119431473 @default.
• W2140998439 cites W2262001859 @default.
• W2140998439 cites W2276408020 @default.
• W2140998439 cites W2314159708 @default.
• W2140998439 cites W2409952111 @default.
• W2140998439 cites W4293241248 @default.
• W2140998439 cites W4300996691 @default.
• W2140998439 doi "https://doi.org/10.1002/(sici)1097-0142(19980801)83:3<449::aid-cncr13>3.0.co;2-w" @default.
• W2140998439 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9690537" @default.
• W2140998439 hasPublicationYear "1998" @default.
• W2140998439 type Work @default.
• W2140998439 sameAs 2140998439 @default.
• W2140998439 citedByCount "112" @default.
• W2140998439 countsByYear W21409984392012 @default.
• W2140998439 countsByYear W21409984392013 @default.
• W2140998439 countsByYear W21409984392014 @default.
• W2140998439 countsByYear W21409984392015 @default.
• W2140998439 countsByYear W21409984392016 @default.
• W2140998439 countsByYear W21409984392017 @default.
• W2140998439 countsByYear W21409984392018 @default.
• W2140998439 countsByYear W21409984392019 @default.
• W2140998439 countsByYear W21409984392020 @default.
• W2140998439 countsByYear W21409984392021 @default.
• W2140998439 crossrefType "journal-article" @default.
• W2140998439 hasAuthorship W2140998439A5014686229 @default.
• W2140998439 hasAuthorship W2140998439A5016989239 @default.
• W2140998439 hasAuthorship W2140998439A5027776467 @default.
• W2140998439 hasAuthorship W2140998439A5039785424 @default.
• W2140998439 hasAuthorship W2140998439A5059710149 @default.
• W2140998439 hasAuthorship W2140998439A5063513320 @default.
• W2140998439 hasAuthorship W2140998439A5067714130 @default.
• W2140998439 hasAuthorship W2140998439A5075667735 @default.
• W2140998439 hasAuthorship W2140998439A5087921958 @default.
• W2140998439 hasBestOaLocation W21409984391 @default.
• W2140998439 hasConcept C126322002 @default.
• W2140998439 hasConcept C141071460 @default.
• W2140998439 hasConcept C146357865 @default.
• W2140998439 hasConcept C151730666 @default.
• W2140998439 hasConcept C2776694085 @default.
• W2140998439 hasConcept C2777955602 @default.
• W2140998439 hasConcept C2778476748 @default.
• W2140998439 hasConcept C2778801703 @default.
• W2140998439 hasConcept C2779338263 @default.
• W2140998439 hasConcept C509974204 @default.
• W2140998439 hasConcept C71924100 @default.
• W2140998439 hasConcept C86803240 @default.
• W2140998439 hasConcept C90924648 @default.
• W2140998439 hasConceptScore W2140998439C126322002 @default.
• W2140998439 hasConceptScore W2140998439C141071460 @default.
• W2140998439 hasConceptScore W2140998439C146357865 @default.
• W2140998439 hasConceptScore W2140998439C151730666 @default.
• W2140998439 hasConceptScore W2140998439C2776694085 @default.
• W2140998439 hasConceptScore W2140998439C2777955602 @default.
• W2140998439 hasConceptScore W2140998439C2778476748 @default.
• W2140998439 hasConceptScore W2140998439C2778801703 @default.
• W2140998439 hasConceptScore W2140998439C2779338263 @default.
• W2140998439 hasConceptScore W2140998439C509974204 @default.
• W2140998439 hasConceptScore W2140998439C71924100 @default.

• next